Sirtuin 2 knockdown inhibits cell proliferation and RAS/ERK signaling, and promotes cell apoptosis and cell cycle arrest in multiple myeloma

Ding,Tianling; Hao,Jie

doi:10.3892/mmr.2021.12400

Sirtuin 2 knockdown inhibits cell proliferation and RAS/ERK signaling, and promotes cell apoptosis and cell cycle arrest in multiple myeloma

Authors:
- Tianling Ding
- Jie Hao
View Affiliations

Affiliations: Department of Hematology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, Department of Hematology, Shanghai Jing'an District Beizhan Hospital, Shanghai 200070, P.R. China
Published online on: September 2, 2021 https://doi.org/10.3892/mmr.2021.12400
Article Number: 760
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the regulatory role of sirtuin 2 (SIRT2) in malignant progression of multiple myeloma (MM) and the potential associated signaling pathways. In total, 30 patients with MM and 15 healthy bone marrow donors were enrolled in the current study and their bone marrow samples were collected to isolate the plasma cells. The expression levels of SIRT2 were detected in MM cell lines (KMS‑28BM, U266, RPMI‑8226 and NCI‑H929) and normal plasma cells (collected from healthy bone marrow donors as the control) via reverse transcription‑quantitative PCR (RT‑qPCR) and western blot analysis. SIRT2 knockdown was established by transfecting two MM cell lines (RPMI‑8226 and NCI‑H929 cells) with short hairpin RNA‑SIRT2 recombinant plasmid; the control group was transfected with a control recombinant plasmid. Subsequently, the effect of SIRT2 knockdown on MM cell proliferation, apoptosis, cell cycle progression and RAS/ERK signaling was investigated via Cell Counting Kit‑8, flow cytometry, RT‑qPCR and western blot assays, respectively. The mRNA and protein expression levels of SIRT2 were increased in U266 (P<0.001), KMS‑28BM (P<0.001), RPMI‑8226 (P<0.001) and NCI‑H929 (P<0.001) cells compared with those in the control cells. In NCI‑H929 and RPMI‑8226 cells, cell proliferation was decreased 48 h (P<0.05) and 72 h (P<0.05) after SIRT2 knockdown. Furthermore, the cell apoptotic rate was elevated 48 h after SIRT2 knockdown (P<0.01). In addition, the percentage of cells at the G0/G1 phase was increased (P<0.01), whereas the percentage of cells at the S phase was reduced (P<0.01) 48 h after SIRT2 knockdown. The expression levels of HRAS and phosphorylated‑ERK were also reduced 48 h after SIRT2 knockdown. In conclusion, SIRT2 was highly expressed in MM cell lines, and knockdown of SIRT2 inhibited MM cell proliferation, inactivated the RAS/ERK signaling pathway, and promoted cell apoptosis and cell cycle arrest.

View Figures

View References

1	Brigle K and Rogers B: Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 33:225–236. 2017. View Article : Google Scholar : PubMed/NCBI
2	Kazandjian D: Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 43:676–681. 2016. View Article : Google Scholar : PubMed/NCBI
3	Rajkumar SV: Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 91:719–734. 2016. View Article : Google Scholar : PubMed/NCBI
4	Nishida H and Yamada T: Monoclonal antibody therapies in multiple myeloma: A challenge to develop novel targets. J Oncol. 2019:60840122019. View Article : Google Scholar : PubMed/NCBI
5	Isa R, Uoshima N, Takahashi R, Nakano-Akamatsu S, Kawata E, Kaneko H, Shimura K, Kamitsuji Y, Takimoto-Shimomura T, Mizutani S, et al: Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma. Ann Hematol. 99:137–145. 2020. View Article : Google Scholar : PubMed/NCBI
6	Swyter S, Schiedel M, Monaldi D, Szunyogh S, Lehotzky A, Rumpf T, Ovádi J, Sippl W and Jung M: New chemical tools for probing activity and inhibition of the NAD(+)-dependent lysine deacylase sirtuin 2. Philos Trans R Soc Lond B Biol Sci. 373:201700832018. View Article : Google Scholar : PubMed/NCBI
7	Liu G, Park SH, Imbesi M, Nathan WJ, Zou X, Zhu Y, Jiang H, Parisiadou L and Gius D: Loss of NAD-dependent protein deacetylase sirtuin-2 alters mitochondrial protein acetylation and dysregulates mitophagy. Antioxid Redox Signal. 26:849–863. 2017. View Article : Google Scholar : PubMed/NCBI
8	Patel VP and Chu CT: Decreased SIRT2 activity leads to altered microtubule dynamics in oxidatively-stressed neuronal cells: Implications for Parkinson's disease. Exp Neurol. 257:170–181. 2014. View Article : Google Scholar : PubMed/NCBI
9	Szego EM, Gerhardt E and Outeiro TF: Sirtuin 2 enhances dopaminergic differentiation via the AKT/GSK-3β/β-catenin pathway. Neurobiol Aging. 56:7–16. 2017. View Article : Google Scholar : PubMed/NCBI
10	Sunami Y, Araki M, Hironaka Y, Morishita S, Kobayashi M, Liew EL, Edahiro Y, Tsutsui M, Ohsaka A and Komatsu N: Inhibition of the NAD-dependent protein deacetylase SIRT2 induces granulocytic differentiation in human leukemia cells. PLoS One. 8:e576332013. View Article : Google Scholar : PubMed/NCBI
11	Jeong SG and Cho GW: The tubulin deacetylase sirtuin-2 regulates neuronal differentiation through the ERK/CREB signaling pathway. Biochem Biophys Res Commun. 482:182–187. 2017. View Article : Google Scholar : PubMed/NCBI
12	Nakagawa T and Guarente L: Sirtuins at a glance. J Cell Sci. 124:833–838. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, et al: SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 20:487–499. 2011. View Article : Google Scholar : PubMed/NCBI
14	Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith DL, Runne H, Gokce O, et al: SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA. 107:7927–7932. 2010. View Article : Google Scholar : PubMed/NCBI
15	Funato K, Hayashi T, Echizen K, Negishi L, Shimizu N, Koyama-Nasu R, Nasu-Nishimura Y, Morishita Y, Tabar V, Todo T, et al: SIRT2-mediated inactivation of p73 is required for glioblastoma tumorigenicity. EMBO Rep. 19:e455872018. View Article : Google Scholar : PubMed/NCBI
16	Xu H, Li Y, Chen L, Wang C, Wang Q, Zhang H, Lin Y, Li Q and Pang T: SIRT2 mediates multidrug resistance in acute myelogenous leukemia cells via ERK1/2 signaling pathway. Int J Oncol. 48:613–623. 2016. View Article : Google Scholar : PubMed/NCBI
17	Li Y, Zhang M, Dorfman RG, Pan Y, Tang D, Xu L, Zhao Z, Zhou Q, Zhou L, Wang Y, et al: SIRT2 promotes the migration and invasion of gastric cancer through RAS/ERK/JNK/MMP-9 pathway by increasing PEPCK1-related metabolism. Neoplasia. 20:745–756. 2018. View Article : Google Scholar : PubMed/NCBI
18	Dan L, Klimenkova O, Klimiankou M, Klusman JH, van den Heuvel-Eibrink MM, Reinhardt D, Welte K and Skokowa J: The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica. 97:551–559. 2012. View Article : Google Scholar : PubMed/NCBI
19	Salazar L, Kashiwada T, Krejci P, Muchowski P, Donoghue D, Wilcox WR and Thompson LM: A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: Activation-dependent regulation of ERK by p85 in multiple myeloma cells. Hum Mol Genet. 18:1951–1961. 2009. View Article : Google Scholar : PubMed/NCBI
20	Hu J and Hu WX: Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments. Cancer Lett. 414:214–221. 2018. View Article : Google Scholar : PubMed/NCBI
21	Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M and Dreyling M; ESMO Guidelines Working Group: Multiple myeloma, : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24 (Suppl 6):vi133–vi137. 2013. View Article : Google Scholar : PubMed/NCBI
22	Shaughnessy J Jr, Gabrea A, Qi Y, Brents L, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel PL and Kuehl M: Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood. 98:217–223. 2001. View Article : Google Scholar : PubMed/NCBI
23	Draube A, Pfister R, Vockerodt M, Schuster S, Kube D, Diehl V and Tesch H: Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement. Ann Hematol. 80:83–89. 2001. View Article : Google Scholar : PubMed/NCBI
24	Piracha ZZ, Kwon H, Saeed U, Kim J, Jung J, Chwae YJ, Park S, Shin HJ and Kim K: Sirtuin 2 isoform 1 enhances hepatitis B virus RNA transcription and DNA synthesis through the AKT/GSK-3β/β-catenin signaling pathway. J Virol. 92:e00955–18. 2018. View Article : Google Scholar
25	Dryden SC, Nahhas FA, Nowak JE, Goustin AS and Tainsky MA: Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol. 23:3173–3185. 2003. View Article : Google Scholar : PubMed/NCBI
26	Nie H, Li Y, Wang C, Chen X, Liu B, Wu D and Ying W: SIRT2 plays a key role in both cell cycle regulation and cell survival of BV2 microglia. Int J Physiol Pathophysiol Pharmacol. 6:166–171. 2014.PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Yang Y, Ding J, Gao ZG and Wang ZJ: A variant in SIRT2 gene 3′-UTR is associated with susceptibility to colorectal cancer. Oncotarget. 8:41021–41025. 2017. View Article : Google Scholar : PubMed/NCBI
29	Ma K, Lu N, Zou F and Meng FZ: Sirtuins as novel targets in the pathogenesis of airway inflammation in bronchial asthma. Eur J Pharmacol. 865:1726702019. View Article : Google Scholar : PubMed/NCBI
30	Zhang Y and Chi D: Overexpression of SIRT2 alleviates neuropathic pain and neuroinflammation through deacetylation of transcription factor nuclear Factor-Kappa B. Inflammation. 41:569–578. 2018. View Article : Google Scholar : PubMed/NCBI
31	Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, Dent P and Grant S: Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood. 112:2439–2449. 2008. View Article : Google Scholar : PubMed/NCBI
32	Mendoza MC, Er EE and Blenis J: The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem Sci. 36:320–328. 2011. View Article : Google Scholar : PubMed/NCBI
33	Song HY, Biancucci M, Kang HJ, O'Callaghan C, Park SH, Principe DR, Jiang H, Yan Y, Satchell KF, Raparia K, et al: SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status. Oncotarget. 7:80336–80349. 2016. View Article : Google Scholar : PubMed/NCBI